Genetic communication between fetus and mother: short- and long-term consequences

American Journal of Obstetrics and Gynecology

Volumn 196, Issue 4, 2007, Pages 372-381

  Holzgreve, Wolfgang ^a   Hahn, Sinuhe ^a   Zhong, Xiao Yan ^a   Lapaire, Olav ^a   Hösli, Irene ^a   Tercanli, Sevgi ^a   Miny, Peter ^a   Diesch, Claude ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD71 ANTIGEN; DNA; TRANSFERRIN;

FEMALE; FETOMATERNAL TRANSFUSION; FETUS; FETUS MONITORING; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC SUSCEPTIBILITY; HUMAN; MATERNAL BLOOD; NON INVASIVE PROCEDURE; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW; Y CHROMOSOME;

FEMALE; GENETIC COUNSELING; GENETIC DISEASES, INBORN; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GESTATIONAL AGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MATERNAL-FETAL EXCHANGE; PLACENTAL CIRCULATION; PREGNANCY; PRENATAL DIAGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 33947611989     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2006.12.013     Document Type: Review

References (137)

1. Holzgreve W., Garritsen H.S., and Ganshirt-Ahlert D. Fetal cells in the maternal circulation. J Reprod Med 37 (1992) 410-418
2. Ganshirt-Ahlert D., Burschyk M., Garritsen H.S., et al. Magnetic cell sorting and the transferrin receptor as potential means of prenatal diagnosis from maternal blood. Am J Obstet Gynecol 166 (1992) 1350-1355
3. Simpson J.L., and Elias S. Isolating fetal cells from maternal blood. Advances in prenatal diagnosis through molecular technology. JAMA 270 (1993) 2357-2361
4. Lo Y.M., Lo E.S., Watson N., et al. Two-way cell traffic between mother and fetus: biologic and clinical implications. Blood 88 (1996) 4390-4395
5. Bianchi D.W. Circulating fetal DNA: its origin and diagnostic potential-a review. Placenta 25 Suppl A (2004) S93-S101
6. Barinaga M. Cells exchanged during pregnancy live on. Science 296 (2002) 2169-2172
7. Hahn S., Huppertz B., and Holzgreve W. Fetal cells and cell free fetal nucleic acids in maternal blood: new tools to study abnormal placentation?. Placenta 26 (2005) 515-526
8. Schmorl G. Pathologisch-anatomische untersuchungen über puerperal-eklampsie (1893), FCW Vogel, Leipzig (Germany)
9. Holzgreve W., Oosterwijk J.C., Brinkhaus R., and Bianchi D.W. Georg Schmorl on trophoblasts in the maternal circulation. Placenta 28 (2006) 1-5
10. Douglas G.W., Thomas L., Carr M., Cullen N.M., and Morris R. Trophoblast in the circulating blood during pregnancy. Am J Obstet Gynecol 78 (1959) 960-973
11. Anker P., Mulcahy H., Chen X.Q., and Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 18 (1999) 65-73
12. Stroun M., Maurice P., Vasioukhin V., et al. The origin and mechanism of circulating DNA. Ann N Y Acad Sci 906 (2000) 161-168
13. Lo Y.M., Corbetta N., Chamberlain P.F., et al. Presence of fetal DNA in maternal plasma and serum. Lancet 350 (1997) 485-487
14. Garvin A., Holzgreve W., and Hahn S. Highly accurate analysis of heterozygous loci by single cell PCR. Nucleic Acids Res 26 (1998) 3468-3472
15. Li Y., Wenzel F., Holzgreve W., and Hahn S. Genotyping fetal paternally inherited SNPs by MALDI-TOF MS using cell-free fetal DNA in maternal plasma: influence of size fractionation. Electrophoresis 27 (2006) 3889-3896
16. Li Y., Holzgreve W., Din E., Vitucci A., and Hahn S. Cell-free DNA in maternal plasma: is it all a question of size?. Ann N Y Acad Sci 1075 (2006) 81-87
17. Li Y., Hahn D., Holzgreve W., and Hahn S. Ready detection of donor-specific single-nucleotide polymorphisms in the urine of renal transplant recipients by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 51 (2005) 1903-1904
18. Li Y., Hahn D., Wenzel F., Holzgreve W., and Hahn S. Detection of SNPs in the plasma of pregnant women and in the urine of kidney transplant recipients by mass spectrometry. Ann N Y Acad Sci 1075 (2006) 144-147
19. Zhong X.Y., Holzgreve W., Hoesli I., and Hahn S. Circulatory corticotropin-releasing hormone mRNA concentrations are increased in women with preterm delivery but not in those who respond to tocolytic treatment. Clin Chem 51 (2005) 635-636
20. Farina A., LeShane E.S., Romero R., et al. High levels of fetal cell-free DNA in maternal serum: a risk factor for spontaneous preterm delivery. Am J Obstet Gynecol 193 (2005) 421-425
21. Ganshirt-Ahlert D., Borjesson-Stoll R., Burschyk M., et al. Detection of fetal trisomies 21 and 18 from maternal blood using triple gradient and magnetic cell sorting. Am J Reprod Immunol 30 (1993) 194-201
22. Troeger C., Holzgreve W., and Hahn S. A comparison of different density gradients and antibodies for enrichment of fetal erythroblasts by MACS. Prenat Diagn 19 (1999) 521-526
23. Mantzaris D., Cram D., Healy C., Howlett D., and Kovacs G. Preliminary report: correct diagnosis of sex in fetal cells isolated from cervical mucus during early pregnancy. Aust N Z J Obstet Gynaecol 45 (2005) 529-532
24. Bianchi D.W., Flint A.F., Pizzimenti M.F., Knoll J.H., and Latt S.A. Isolation of fetal DNA from nucleated erythrocytes in maternal blood. Proc Natl Acad Sci U S A 87 (1990) 3279-3283
25. Elias S., Price J., Dockter M., Wachtel S., et al. First trimester prenatal diagnosis of trisomy 21 in fetal cells from maternal blood. Lancet 340 (1992) 1033
26. Holzgreve W., Garritsen H.S., Tercanli S., Miny P., Nippert I., and Ganshirt D. Noninvasive prenatal diagnosis. Strategy for a clinical trial. Ann N Y Acad Sci 731 (1994) 253-256
27. Bianchi D.W., Simpson J.L., Jackson L.G., et al., National Institute of Child Health and Human Development Fetal Cell Isolation Study. Fetal gender and aneuploidy detection using fetal cells in maternal blood: analysis of NIFTY I data. Prenat Diagn 22 (2002) 609-615
28. Zimmermann B., Holzgreve W., Zhong X.Y., and Hahn S. Inability to clonally expand fetal progenitors from maternal blood. Fetal Diagn Ther 17 (2002) 97-100
29. Babochkina T., Mergenthaler S., De Napoli G., et al. Numerous erythroblasts in maternal blood are impervious to fluorescent in situ hybridization analysis, a feature related to a dense compact nucleus with apoptotic character. Haematologica 90 (2005) 740-745
30. Johnson K.L., Dukes K.A., Vidaver J., et al. Interlaboratory comparison of fetal male DNA detection from common maternal plasma samples by real-time PCR. Clin Chem 50 (2004) 516-521
31. Bischoff F.Z., Hahn S., Johnson K.L., et al. Intact fetal cells in maternal plasma: are they really there?. Lancet 361 (2003) 139-140
32. Troeger C., Zhong X.Y., Burgemeister R., et al. Approximately half of the erythroblasts in maternal blood are of fetal origin. Mol Hum Reprod 5 (1999) 1162-1165
33. Faas B.H., Beuling E.A., Christiaens G.C., von dem Borne A.E., and van der Schoot C.E. Detection of fetal RHD-specific sequences in maternal plasma. Lancet 352 (1998) 1196
34. Lo Y.M., Hjelm N.M., Fidler C., et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med 339 (1998) 1734-1738
35. Zhong X.Y., Holzgreve W., and Hahn S. Detection of fetal Rhesus D and sex using fetal DNA from maternal plasma by multiplex polymerase chain reaction. BJOG 107 (2000) 766-769
36. Zhong X.Y., Hahn S., and Holzgreve W. Prenatal identification of fetal genetic traits. Lancet 357 (2001) 310-311
37. Gautier E., Benachi A., Giovangrandi Y., et al. Fetal RhD genotyping by maternal serum analysis: a two-year experience. Am J Obstet Gynecol 192 (2005) 666-669
38. Van der Schoot C.E., Soussan A.A., Koelewijn J., Bonsel G., Paget-Christiaens L.G., and de Haas M. Non-invasive antenatal RHD typing. Transfus Clin Biol 13 (2006) 53-57
39. Rijnders R.J., Christiaens G.C., Bossers B., Van Der Smagt J.J., Van Der Schoot C., and De Haas M. Clinical applications of cell-free fetal DNA from maternal plasma. Obstet Gynecol 103 (2004) 157-164
40. Moise K.J. Fetal RhD typing with free DNA in maternal plasma. Am J Obstet Gynecol 192 (2005) 663-665
41. Illanes S., Avent N., and Soothill P.W. Cell-free fetal DNA in maternal plasma: an important advance to link fetal genetics to obstetric ultrasound. Ultrasound Obstet Gynecol 25 (2005) 317-322
42. Geifman-Holtzman O., Grotegut C.A., and Gaughan J.P. Diagnostic accuracy of noninvasive fetal Rh genotyping from maternal blood-a meta-analysis. Am J Obstet Gynecol 195 (2006) 1163-1173
43. Costa J.M., Benachi A., Gautier E., Jouannic J.M., Ernault P., and Dumez Y. First-trimester fetal sex determination in maternal serum using real-time PCR. Prenat Diagn 21 (2001) 1070-1074
44. Martinhago C.D., De Oliveira R.M., Tomitao Canas M.D., et al. Accuracy of fetal gender determination in maternal plasma at 5 and 6 weeks of pregnancy. Prenat Diagn 26 (2006) 1219-1223
45. Santacroce R., Vecchione G., Tomaiyolo M., et al. Identification of fetal gender in maternal blood is a helpful tool in the prenatal diagnosis of haemophilia. Haemophilia 12 (2006) 417-422
46. Smith R.P., Lombaard H., and Soothill P.W. The obstetrician's view: ethical and societal implications of non-invasive prenatal diagnosis. Prenat Diagn 26 (2006) 631-634
47. George S.M. Millions of missing girls: from fetal sexing to high technology sex selection in India. Prenat Diagn 26 (2006) 604-609
48. Kaiser J. Prenatal diagnosis: an earlier look at baby's genes. Science 309 (2005) 1476-1478
49. Saito H., Sekizawa A., Morimoto T., Suzuki M., and Yanaihara T. Prenatal DNA diagnosis of a single-gene disorder from maternal plasma. Lancet 356 (2000) 1170
50. Li Y., Holzgreve W., Page-Christiaens G.C., Gille J.J., and Hahn S. Improved prenatal detection of a fetal point mutation for achondroplasia by the use of size-fractionated circulatory DNA in maternal plasma-case report. Prenat Diagn 24 (2004) 896-898
51. Amicucci P., Gennarelli M., Novelli G., and Dallapiccola B. Prenatal diagnosis of myotonic dystrophy using fetal DNA obtained from maternal plasma. Clin Chem 46 (2000) 301-302
52. Li Y., Di Naro E., Vitucci A., Zimmermann B., Holzgreve W., and Hahn S. Detection of paternally inherited fetal point mutations for beta-thalassemia using size-fractionated cell-free DNA in maternal plasma. JAMA 293 (2005) 843-849
53. Saker A., Benachi A., Bonnefont J.P., et al. Genetic characterisation of circulating fetal cells allows non-invasive prenatal diagnosis of cystic fibrosis. Prenat Diagn 26 (2006) 906-916
54. Tungwiwat W., Fucharoen S., Fucharoen G., Ratanasiri T., and Sanchaisuriya K. Development and application of a real-time quantitative PCR for prenatal detection of fetal alpha(0)-thalassemia from maternal plasma. Ann N Y Acad Sci 1075 (2006) 103-107
55. Zhong X., Hahn S., Kiefer V., and Holzgreve W. Is the quantity of circulatory cell-free DNA in human plasma and serum samples associated with gender, age and frequency of blood donations?. Ann Hematol 86 (2006) 139-143
56. Zhong X.Y., Burk M.R., Troeger C., Jackson L.R., Holzgreve W., and Hahn S. Fetal DNA in maternal plasma is elevated in pregnancies with aneuploid fetuses. Prenat Diagn 20 (2000) 795-798
57. Samura O., Sohda S., Johnson K.L., et al. Diagnosis of trisomy 21 in fetal nucleated erythrocytes from maternal blood by use of short tandem repeat sequences. Clin Chem 47 (2001) 1622-1626
58. Aractingi S., Berkane N., Bertheau P., et al. Fetal DNA in skin of polymorphic eruptions of pregnancy. Lancet 352 (1998) 1898-1901
59. Holmes R.C., and Black M.M. The specific dermatoses of pregnancy: a reappraisal with special emphasis on a proposed simplified clinical classification. Clin Exp Dermatol 7 (1982) 65-73
60. Holzgreve W., and Vakilzadeh F. Herpes gestationis: clinical and optic immunofluorescence findings. Zentralbl Gynakol 104 (1982) 1462-1467
61. Sibai B., Dekker G., and Kupferminc M. Pre-eclampsia. Lancet 365 (2005) 785-799
62. Roberts J.M., Pearson G.D., Cutler J.A., and Lindheimer M.D. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertens Pregnancy 22 (2003) 109-127
63. Sattar N., and Greer I.A. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening?. BMJ 325 (2002) 157-160
64. Ganshirt D., Smeets F.W., Dohr A., et al. Enrichment of fetal nucleated red blood cells from the maternal circulation for prenatal diagnosis: experiences with triple density gradient and MACS based on more than 600 cases. Fetal Diagn Ther 13 (1998) 276-286
65. Holzgreve W., Ghezzi F., Di Naro E., Ganshirt D., Maymon E., and Hahn S. Disturbed feto-maternal cell traffic in preeclampsia. Obstet Gynecol 91 (1998) 669-672
66. Lo Y.M., Leung T.N., Tein M.S., et al. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem 45 (1999) 184-188
67. Jansen M.W., Korver-Hakkennes K., van Leenen D., et al. Significantly higher number of fetal cells in the maternal circulation of women with pre-eclampsia. Prenat Diagn 21 (2001) 1022-1026
68. Farina A., Sekizawa A., Iwasaki M., Matsuoka R., Ichizuka K., and Okai T. Total cell-free DNA (beta-globin gene) distribution in maternal plasma at the second trimester: a new prospective for preeclampsia screening. Prenat Diagn 24 (2004) 722-726
69. Zhong X.Y., Laivuori H., Livingston J.C., et al. Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia. Am J Obstet Gynecol 184 (2001) 414-419
70. Zhong X.Y., Holzgreve W., and Hahn S. Circulatory fetal and maternal DNA in pregnancies at risk and those affected by preeclampsia. Ann N Y Acad Sci 945 (2001) 138-140
71. Stamilio D.M., Sehdev H.M., Morgan M.A., Propert K., and Macones G.A. Can antenatal clinical and biochemical markers predict the development of severe preeclampsia?. Am J Obstet Gynecol 182 (2000) 589-594
72. Conde-Agudelo A., Villar J., and Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 104 (2004) 1367-1391
73. Duckitt K., and Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 330 (2005) 565
74. Yu C.K., Smith G.C., Papageorghiou A.T., Cacho A.M., and Nicolaides K.H. An integrated model for the prediction of pre-eclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol 195 (2006) 330
75. Holzgreve W., Li J.J., Steinborn A., et al. Elevation in erythroblast count in maternal blood before the onset of preeclampsia. Am J Obstet Gynecol 184 (2001) 165-168
76. Zhong X.Y., Holzgreve W., and Hahn S. The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia. Hypertens Pregnancy 21 (2002) 77-83
77. Levine R.J., Qian C., Leshane E.S., et al. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynecol 190 (2004) 707-713
78. Lau T.W., Leung T.N., Chan L.Y., et al. Fetal DNA clearance from maternal plasma is impaired in preeclampsia. Clin Chem 48 (2002) 2141-2146
79. Venkatesha S., Toporsian M., Lam C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12 (2006) 642-649
80. Levine R.J., Lam C., Qian C., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355 (2006) 992-1005
81. Farina A., Sekizawa A., Sugito Y., et al. Fetal DNA in maternal plasma as a screening variable for preeclampsia. A preliminary nonparametric analysis of detection rate in low-risk nonsymptomatic patients. Prenat Diagn 24 (2004) 83-86
82. Holzgreve W., and Hahn S. Novel molecular biological approaches for the diagnosis of preeclampsia. Clin Chem 45 (1999) 451-452
83. Troeger C., Holzgreve W., Ladewig A., Zhong X.Y., and Hahn S. Examination of maternal plasma erythropoietin and activin A concentrations with regard to circulatory erythroblast levels in normal and preeclamptic pregnancies. Fetal Diagn Ther 21 (2006) 156-160
84. Pijnenborg R., Ball E., Bulmer J.N., Hanssens M., Robson S.C., and Vercruysse L. In vivo analysis of trophoblast cell invasion in the human. Methods Mol Med 122 (2006) 11-44
85. Kadyrov M., Kingdom J.C., and Huppertz B. Divergent trophoblast invasion and apoptosis in placental bed spiral arteries from pregnancies complicated by maternal anemia and early-onset preeclampsia/intrauterine growth restriction. Am J Obstet Gynecol 194 (2006) 557-563
86. Matijevic R., and Johnston T. In vivo assessment of failed trophoblastic invasion of the spiral arteries in pre-eclampsia. Br J Obstet Gynaecol 106 (1999) 78-82
87. Redman C.W., and Sargent I.L. Placental debris, oxidative stress and pre-eclampsia. Placenta 21 (2000) 597-602
88. Roberts J.M., and Hubel C.A. Is oxidative stress the link in the two-stage model of pre-eclampsia?. Lancet 354 (1999) 788-789
89. Tjoa M.L., Cindrova-Davies T., Spasic-Boskovic O., Bianchi D.W., and Burton G.J. Trophoblastic oxidative stress and the release of cell-free feto-placental DNA. Am J Pathol 169 (2006) 400-404
90. Orozco A.F., Bischoff F.Z., Horne C., Popek E., Simpson J.L., and Lewis D.E. Hypoxia-induced membrane-bound apoptotic DNA particles: potential mechanism of fetal DNA in maternal plasma. Ann N Y Acad Sci 1075 (2006) 57-62
91. Redman C.W., Sacks G.P., and Sargent I.L. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 180 (1999) 499-506
92. Sacks G.P., Studena K., Sargent K., and Redman C.W. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol 179 (1998) 80-86
93. Martin Jr. J.N., Perry Jr. K.G., Blake P.G., May W.A., Moore A., and Robinette L. Better maternal outcomes are achieved with dexamethasone therapy for postpartum HELLP (hemolysis, elevated liver enzymes, and thrombocytopenia) syndrome. Am J Obstet Gynecol 177 (1997) 1011-1017
94. Martin Jr. J.N., Thigpen B.D., Rose C.H., Cushman J., Moore A., and May W.L. Maternal benefit of high-dose intravenous corticosteroid therapy for HELLP syndrome. Am J Obstet Gynecol 189 (2003) 830-834
95. Beller F.K., Schmidt E.H., Holzgreve W., and Hauss J. Septicemia during pregnancy: a study in different species of experimental animals. Am J Obstet Gynecol 151 (1985) 967-975
96. Redman C.W., and Sargent I.L. Placental debris, oxidative stress and pre-eclampsia. Placenta 21 (2000) 597-602
97. Many A., Hubel C.A., Fisher S.J., Roberts J.M., and Zhou Y. Invasive cytotrophoblasts manifest evidence of oxidative stress in preeclampsia. Am J Pathol 156 (2000) 321-331
98. Zhong X.Y., Holzgreve W., and Hahn S. Cell-free fetal DNA in the maternal circulation does not stem from the transplacental passage of fetal erythroblasts. Mol Hum Reprod 8 (2002) 864-870
99. Redman C.W., and Sargent I.L. Latest advances in understanding preeclampsia. Science 308 (2005) 1592-1594
100. Gupta A.K., Holzgreve W., and Hahn S. Microparticle-free placentally derived soluble factors downmodulate the response of activated T cells. Hum Immunol 66 (2005) 977-984
101. Knight M., Redman C.W., Linton E.A., and Sargent I.L. Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies. Br J Obstet Gynaecol 105 (1998) 632-640
102. Zhong X.Y., Wang Y., Chen S., et al. Can circulatory fetal DNA be used to study placentation at high altitude?. Ann N Y Acad Sci 1022 (2004) 124-128
103. Taylor R.N., de Groot C.J., Cho Y.K., and Lim K.H. Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia. Semin Reprod Endocrinol 16 (1998) 17-31
104. VanWijk M.J., Nieuwland R., Boer K., van der Post J.A., VanBavel E., and Sturk A. Microparticle subpopulations are increased in preeclampsia: possible involvement in vascular dysfunction?. Am J Obstet Gynecol 187 (2002) 450-456
105. Moran P., Lindheimer M.D., and Davison J.M. The renal response to preeclampsia. Semin Nephrol 24 (2004) 588-595
106. Rusterholz C., Gupta A.K., Huppertz B., Holzgreve W., and Hahn S. Soluble factors released by placental villous tissue: interleukin-1 is a potential mediator of endothelial dysfunction. Am J Obstet Gynecol 192 (2005) 618-624
107. Zhong X.Y., Gebhardt S., Hillermann R., Tofa K.C., Holzgreve W., and Hahn S. Circulatory nucleosome levels are significantly increased in early and late-onset preeclampsia. Prenat Diagn 25 (2005) 700-703
108. Gupta A.K., Hasler P., Holzgreve W., Gebhardt S., and Hahn S. Induction of neutrophil extracellular DNA lattices by placental microparticles and IL-8 and their presence in preeclampsia. Hum Immunol 66 (2005) 1146-1154
109. Brinkmann V., Reichard U., Goosmann C., et al. Neutrophil extracellular traps kill bacteria. Science 303 (2004) 1532-1535
110. Gupta A.K., Hasler P., Holzgreve W., Gebhardt S., and Hahn S. Induction of neutrophil extracellular DNA lattices by placental microparticles and IL-8 and their presence in preeclampsia. Hum Immunol 66 (2005) 1146-1154
111. Hahn S., Gupta A.K., Troeger C., Rusterholz C., and Holzgreve W. Disturbances in placental immunology: ready for therapeutic interventions?. Springer Semin Immunopathol 27 (2006) 477-493
112. Klonoff Cohen H.S., Savitz D.A., Cefalo R.C., and McCann M.F. An epidemiologic study of contraception and preeclampsia. JAMA 262 (1989) 3143-3147
113. Soderstrom-Anttila V., and Hovatta O. An oocyte donation program with goserelin down-regulation of voluntary donors. Acta Obstet Gynecol Scand 74 (1995) 288-292
114. Wang J.X., Knottnerus A.M., Schuit G., Norman R.J., Chan A., and Dekker G.A. Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia. Lancet 359 (2002) 673-674
115. Feeney J.G., Tovey L.A., and Scott J.S. Influence of previous blood-transfusion on incidence of pre-eclampsia. Lancet 1 (1997) 874-875
116. Robillard P.Y., Hulsey T.C., Perianin J., Janky E., Miri E.H., and Papiernik E. Association of pregnancy-induced hypertension with duration of sexual cohabitation before conception. Lancet 344 (1994) 973-975
117. Dekker G. The partner's role in the etiology of preeclampsia. J Reprod Immunol 57 (2002) 203-215
118. Medawar P.B. Immunological tolerance. Science 133 (1961) 303-306
119. Uckan D., Steele A., Cherry B., et al. Trophoblasts express Fas ligand: a proposed mechanism for immune privilege in placenta and maternal invasion. Mol Hum Reprod 3 (1997) 655-662
120. O'Shaughnessy K.M., Ferraro F., Fu B., Downing S., and Morris N.H. Identification of monozygotic twins that are concordant for preeclampsia. Am J Obstet Gynecol 182 (2000) 1156-1157
121. Lie R.T., Rasmussen S., Brunborg H., Gjessing H.K., Lie-Nielsen E., and Irgens L.M. Fetal and maternal contributions to risk of pre-eclampsia: population based study. BMJ 316 (1998) 1343-1347
122. Laivuori H., Lahermo P., Ollikainen V., et al. Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families. Am J Hum Genet 72 (2003) 168-177
123. Zhong X.Y., Gebhardt S., Hillermann R., Tofa K.C., Holzgreve W., and Hahn S. Parallel assessment of circulatory fetal DNA and corticotropin-releasing hormone mRNA in early- and late-onset preeclampsia. Clin Chem 51 (2005) 1730-1733
124. Zhong X.Y., Holzgreve W., Gebhardt S., et al. Minimal alteration in the ratio of circulatory fetal DNA to fetal corticotropin-releasing hormone mRNA level in preeclampsia. Fetal Diagn Ther 21 (2006) 246-249
125. Nelson J.L. Maternal-fetal immunology and autoimmune disease: is some autoimmune disease auto-alloimmune or allo-autoimmune?. Arthritis Rheum 39 (1996) 191-194
126. Nelson J.L. Microchimerism and the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 10 (1998) 564-571
127. Artlett C.M., Smith J.B., and Jimenez S.A. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 338 (1998) 1186-1191
128. Scaletti C., Vultaggio A., Maggi E., Romagnani S., and Piccinni M.P. Microchimerism and systemic sclerosis. Int Arch Allergy Immunol 125 (2001) 196-202
129. Artlett C.M. Pathophysiology of fetal microchimeric cells. Clin Chim Acta 360 (2005) 1-8
130. Khosrotehrani K., and Bianchi D.W. Multi-lineage potential of fetal cells in maternal tissue: a legacy in reverse. J Cell Sci 118 (2005) 1559-1563
131. Maloney S., Smith A., Furst D.E., et al. Microchimerism of maternal origin persists into adult life. J Clin Invest 104 (1999) 41-47
132. Srivatsa B., Srivatsa S., Johnson K.L., Samura O., Lee S.L., and Bianchi D.W. Microchimerism of presumed fetal origin in thyroid specimens from women: a case-control study. Lancet 358 (2001) 2034-2038
133. Klintschar M., Schwaiger P., Mannweiler S., Regauer S., and Kleiber M. Evidence of fetal microchimerism in Hashimoto's thyroiditis. J Clin Endocrinol Metab 86 (2001) 2494-2498
134. Barinaga M. Cells exchanged during pregnancy live on. Science 296 (2002) 2169-2172
135. Toda I., Kuwana M., Tsubota K., and Kawakami Y. Lack of evidence for an increased microchimerism in the circulation of patients with Sjogren's syndrome. Ann Rheum Dis 60 (2001) 248-253
136. Aractingi S., Sibilia J., Meignin V., et al. Presence of microchimerism in labial salivary glands in systemic sclerosis but not in Sjogren's syndrome. Arthritis Rheum 46 (2002) 1039-1043
137. Wang Y., Iwatani H., Ito T., et al. Fetal cells in mother rats contribute to the remodeling of liver and kidney after injury. Biochem Biophys Res Commun 325 (2004) 961-967